SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 2192393

Cover Image

PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 2192393

Microbiome Therapeutics Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2026-2035

PUBLISHED:
PAGES: 193 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
PDF & Excel (Single User License)
USD 4850
PDF & Excel (Multi User License)
USD 6050
PDF & Excel (Enterprise User License)
USD 8350

Add to Cart

The Microbiome Therapeutics Market reached USD 255 million in 2025 and is projected to grow at 31.0% CAGR from 2026 to 2035. The market is expected to cross USD 3.92 billion valuation by 2035.

Market Scope
Start Year2025
Forecast Year2026-2035
Start Value$255 Million
Forecast Value$3.92 Billion
CAGR31%

Approved microbiota-based products establish a regulatory and commercial foundation for further development. Experience with Rebyota and VOWST clarifies expectations for donor screening, consistent manufacturing, safety follow-up, and clinical evidence. Providers and payers can become more familiar with standardized therapies that previously depended more heavily on investigational or procedure-based care. Inflammatory bowel disease creates an important expansion opportunity because some patients remain inadequately controlled with existing treatment. Developers are investing in defined bacterial products intended to support more durable disease management. Successful late-stage evidence could extend adoption beyond specialist recurrent infection care into broader gastroenterology pathways. Oncology offers another development direction. Microbiome-directed adjuncts could become relevant where they improve the effectiveness or tolerability of established immunotherapy. These settings involve complex clinical care and differentiated pricing opportunities. Commercial progress nevertheless depends on reproducible results and a workable role within combination treatment. The market's drivers therefore combine approved-product experience with indication-specific development rather than assuming that microbiome activity alone establishes clinical or commercial value.

Based on product type, FMT Procedures and Standardized Products are projected to reach USD 2.50 billion by 2035. Traceability, consistent administration, and quality assurance support the category's established commercial role. Manufactured products provide a clearer route into hospital purchasing and payer engagement than variable historical approaches. Existing workflows can also provide an operating foundation for wider category adoption as more defined therapies develop.

By application, Clostridioides difficile infection is projected to generate USD 980 million by 2035. Approved launches, patient identification pathways, and the need to prevent recurrence after antibiotics support demand. This application provides an established evidence and revenue base. Development in other indications can broaden the overall mix without removing the continuing clinical importance of recurrent infection treatment and standardized access to microbiota-based products.

The North America microbiome therapeutics market generated USD 158 million in 2025. Regulatory precedents, specialty networks, reimbursement experience, and distribution channels support commercialization. Provider familiarity and payer-navigation capabilities make the region relevant for emerging indications as well as established treatments. These operating conditions influence launch opportunities, while international adoption progressively expands the geographic base of demand for microbiota-based and live biotherapeutic products.

Ferring Pharmaceuticals held over 21% market share in 2025. Rebyota gave the company experience with standardized FMT commercialization, regulatory engagement, and provider education in recurrent infection care. Its strategic review of the product indicates potential changes in ownership or partnership arrangements. The company's position reflects both early approved-product access and the practical work required to establish a new specialty treatment category.

Some of the major players in this market are Seres Therapeutics, Nestle Health Science, OPENBIOME, Vedanta Biosciences, and MaaT Pharma. VOWST's oral format differentiates its ambulatory offering, where ease of administration and adherence influence selection. OPENBIOME contributes donor screening, stool banking, and hospital support capabilities relevant to safety and quality standards. Vedanta is developing defined bacterial consortia, while MaaT Pharma pursues a full-spectrum approach in severe gastrointestinal graft-versus-host disease. Other developers address precision treatment, bacteriophages, metabolic applications, and additional next-generation mechanisms. Hospital programs and regional suppliers also contribute to the landscape. Manufacturing controls, clinical results, regulatory experience, and specialty-care access shape competition. As applications broaden, developers need to demonstrate scalable production and meaningful therapeutic differentiation. These requirements give operational capabilities commercial importance alongside scientific innovation, particularly where products must fit established treatment protocols and satisfy payer expectations before wider routine use. Defined-consortium development illustrates how product design is becoming more indication-specific. This broadens the innovation landscape while maintaining the need for rigorous manufacturing and clinical evidence across different therapeutic approaches and delivery formats.

Product Code: 13684

Table of Contents

Chapter 1. Research Methodology

  • 1.1 Research approach
  • 1.2 Quality Commitments
    • 1.2.1 GMI AI policy & data integrity commitment
      • 1.2.1.1 Source consistency protocol
  • 1.3 Research Trail & Confidence Scoring
    • 1.3.1 Research Trail Components
    • 1.3.2 Scoring Components
  • 1.4 Data Collection
    • 1.4.1 Partial list of primary sources
  • 1.5 Data mining sources
    • 1.5.1 Paid sources
      • 1.5.1.1 Sources, by region
  • 1.6 Base estimates and calculations
    • 1.6.1 Base year calculation
  • 1.7 Forecast model
    • 1.7.1 Quantified market impact analysis
      • 1.7.1.1 Mathematical impact of growth parameters on forecast
  • 1.8 Research transparency addendum
    • 1.8.1 Source attribution framework
    • 1.8.2 Quality assurance metrics
    • 1.8.3 Our commitment to trust

Chapter 2. Executive Summary

  • 2.1 Industry 360° synopsis
  • 2.2 Key market trends
    • 2.2.1 Type trends
    • 2.2.2 Application trends
    • 2.2.3 Regional trends
  • 2.3 TAM analysis, 2027-2035
  • 2.4 CXO perspectives: strategic imperatives

Chapter 3. Industry Insights

  • 3.1 Industry ecosystem analysis
    • 3.1.1 Supplier Landscape
    • 3.1.2 Profit Margin
    • 3.1.3 Cost structure
    • 3.1.4 Value addition at each stage
    • 3.1.5 Factor affecting the value chain
    • 3.1.6 Disruptions
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Rising burden of chronic diseases
      • 3.2.1.2 Advancements in microbiome research
      • 3.2.1.3 Increasing investment and partnerships for drug development
    • 3.2.2 Industry pitfalls and challenges
      • 3.2.2.1 Regulatory and clinical challenges
      • 3.2.2.2 Limited availability in developing areas
    • 3.2.3 Market opportunities
  • 3.3 Growth potential analysis
  • 3.4 Pricing Analysis (Driven by Primary Research)
    • 3.4.1 Historical Price Trend Analysis
    • 3.4.2 Pricing Strategy by Player Type (Premium / Value / Cost-plus)
  • 3.5 Regulatory landscape
    • 3.5.1 North America
    • 3.5.2 Europe
    • 3.5.3 Asia-Pacific
    • 3.5.4 Latin America
    • 3.5.5 Middle East and Africa
  • 3.6 Porter's analysis
  • 3.7 PESTEL analysis
  • 3.8 Trade Data Analysis (Based on Paid Database)
    • 3.8.1 Import/Export Volume & Value Trends
    • 3.8.2 Key Trade Corridors & Tariff Impact
  • 3.9 Impact of AI & Generative AI on the Market (Driven by Primary Research)
    • 3.9.1 AI-Driven Disruption of Existing Business Models
    • 3.9.2 GenAI Use Cases & Adoption Roadmap by Segment
    • 3.9.3 Risks, Limitations & Regulatory Considerations
  • 3.10 Patent / IP Landscape
  • 3.11 Medical Infrastructure Landscape
  • 3.12 Epidemiology / Disease Burden
  • 3.13 Pipeline Analysis

Chapter 4. Competitive Landscape, 2025

  • 4.1 Introduction
  • 4.2 Company market share analysis
    • 4.2.1 By Region
      • 4.2.1.1 North America
      • 4.2.1.2 Europe
      • 4.2.1.3 Asia-Pacific
      • 4.2.1.4 Latin America
      • 4.2.1.5 Middle East and Africa
    • 4.2.2 Market Concentration Analysis
  • 4.3 Competitive analysis of major market players
  • 4.4 Competitive positioning matrix
  • 4.5 Key developments
    • 4.5.1 Mergers & acquisitions
    • 4.5.2 Partnerships & collaborations
    • 4.5.3 New product launches
    • 4.5.4 Expansion plans and funding
  • 4.6 Company tier benchmarking
    • 4.6.1 Tier classification criteria & qualifying thresholds
    • 4.6.2 Tier positioning matrix by revenue, geography & innovation

Chapter 5. Market Estimates and Forecast, By Type, 2022 - 2035 ($ Mn)

  • 5.1 Key trends
  • 5.2 Fecal microbiota transplantation (FMT)
  • 5.3 Microbiome drugs

Chapter 6. Market Estimates and Forecast, By Application, 2022 - 2035 ($ Mn)

  • 6.1 Key trends
  • 6.2 Inflammatory bowel disease (IBD)
  • 6.3 Cancer
  • 6.4 Clostridioides difficile (C. difficile)
  • 6.5 Diabetes
  • 6.6 Other applications

Chapter 7. Market Estimates and Forecast, By Region, 2022 - 2035 ($ Mn)

  • 7.1 Key trends
  • 7.2 North America
    • 7.2.1 U.S.
    • 7.2.2 Canada
  • 7.3 Europe
    • 7.3.1 Germany
    • 7.3.2 UK
    • 7.3.3 France
    • 7.3.4 Spain
    • 7.3.5 Italy
    • 7.3.6 Netherlands
    • 7.3.7 Rest of Europe
  • 7.4 Asia Pacific
    • 7.4.1 China
    • 7.4.2 Japan
    • 7.4.3 India
    • 7.4.4 Australia
    • 7.4.5 South Korea
    • 7.4.6 Rest of Asia-Pacific
  • 7.5 Latin America
    • 7.5.1 Brazil
    • 7.5.2 Mexico
    • 7.5.3 Argentina
    • 7.5.4 Rest of Latin America
  • 7.6 Middle East and Africa
    • 7.6.1 South Africa
    • 7.6.2 Saudi Arabia
    • 7.6.3 UAE
    • 7.6.4 Rest of Middle East and Africa

Chapter 8. Company Profiles

  • 8.1 Global Player
    • 8.1.1 Ferring Pharmaceuticals
    • 8.1.2 Seres Therapeutics
    • 8.1.3 Vedanta Biosciences
    • 8.1.4 Finch
  • 8.2 Regional Player
    • 8.2.1 Enterome
    • 8.2.2 MaaT Pharma
    • 8.2.3 OPENBIOME
    • 8.2.4 Intralytix
    • 8.2.5 LNC Therapeutics
    • 8.2.6 Inlife
  • 8.3 Emerging Player
    • 8.3.1 Aardvark Therapeutics
    • 8.3.2 AOB Pharma
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!